Abstract: This present invention relates to a face mask with an integrated communication system that ensures the safety of the wearer while allowing the same to effectively communicate with others while wearing the face mask. The face mask features a voice modulator having a microphone and a speaker removably attached to the mask body. The wearer can easily speak into the microphone and the voice of the wearer is captured by the microphone and is clearly projected and modulated by the speaker. Additionally, the wearer may adjust the volume of the speaker as per the needs and requirements of the wearer.

Abstract: Systems and methods for inhibiting atherosclerosis using FoxP3+ CD8 T-cells (TcREG). Osteoclasts are induced to produce FoxP3+ CD8 T-cells (TcREG) through introduction of a low-dose of a RANK agonist such as RANKL. The RANKL was found to best work when provided in accordance with a schedule resulting in a pulsed administration.

Abstract: Systems and methods for inhibiting atherosclerosis using FoxP3+ CD8 T-cells (TcREG). Osteoclasts are induced to produce FoxP3+ CD8 T-cells (TcREG) through introduction of a low-dose of a RANK agonist suck as RANKL. The RANKL was found to best work when provided in accordance with a schedule resulting in a pulsed administration.

Abstract: Systems and methods for inhibiting atherosclerosis using FoxP3+ CD8 T-cells (TcREG). Osteoclasts are induced to produce FoxP3+ CD8 T-cells (TcREG) through introduction of a low-dose of a RANK agonist such as RANKL. The RANKL was found to best work when provided in accordance with a schedule resulting in a pulsed administration.

Abstract: Systems and methods for inhibiting atherosclerosis using FoxP3+ CD8 T-cells (TcREG). Osteoclasts are induced to produce FoxP3+ CD8 T-cells (TcREG) through introduction of a low-dose of a RANK agonist suck as RANKL. The RANKL was found to best work when provided in accordance with a schedule resulting in a pulsed administration.

Abstract: The invention provides methods of determining whether a cancer in a subject is responsive to anti-TGF-? therapy. In some embodiments, the invention further provides for the administration of an anti-TGF-? therapy cancer therapy to the subject.

Abstract: The invention provides a method of treating cancer in a subject comprising administering to said subject an miRNA that inhibits Six1. In some embodiments, the invention further provides for the administration of a second cancer therapy to the subject.

Abstract: The present invention is directed to methods and compositions wherein nucleic acids are associated with a solid phase that comprises a carboxylated substrate. In specific embodiments, precipitation of the nucleic acids occurs in the absence of salt.

Abstract: The present invention is directed to methods and compositions wherein nucleic acids are associated with a solid phase that comprises a carboxylated substrate. In specific embodiments, precipitation of the nucleic acids occurs in the absence of salt.

Abstract: The present invention is directed to methods and compositions wherein nucleic acids are associated with a solid phase that comprises a carboxylated substrate. In specific embodiments, precipitation of the nucleic acids occurs in the absence of salt.